Publicacions (276) Publicacions de FEDERICO PULIDO ORTEGA

2024

  1. Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians

    The Lancet HIV

2023

  1. Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age

    HIV Medicine, Vol. 24, Núm. 1, pp. 27-36

  2. Comparison of the Accuracy of the 7-Item HADS Depression Subscale and 14-Item Total HADS for Screening for Major Depression: A Systematic Review and Individual Participant Data Meta-Analysis

    Psychological Assessment, Vol. 35, Núm. 2, pp. 94-114

  3. Corrigendum to “Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)” (EBioMedicine (2020) 55, (S2352396420301547), (10.1016/j.ebiom.2020.102779))

    eBioMedicine

  4. Deep Sequencing on Proviral DNA: More Questions than Answers

    Journal of acquired immune deficiency syndromes (1999)

  5. Healthcare outcomes in patients with HIV infection at a tertiary hospital during the COVID-19 pandemic

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 41, Núm. 3, pp. 149-154

2022

  1. 48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort

    PLoS ONE, Vol. 17, Núm. 11 November

  2. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  3. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

  4. Incidence and Severity of SARS-CoV-2 Infection in HIV-Infected Individuals during the First Year of the Pandemic

    Journal of Acquired Immune Deficiency Syndromes, Vol. 89, Núm. 5, pp. 511-518

  5. Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance

    Open Forum Infectious Diseases, Vol. 9, Núm. 11

  6. Past and future of HIV infection. A document based on expert opinion

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 35, Núm. 2, pp. 131-156

  7. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

  8. Severe diarrhea by Cystoisospora belli in a well controlled HIV-infected patient

    AIDS (London, England), Vol. 36, Núm. 3, pp. 485-486

2021

  1. Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial

    Infectious Diseases and Therapy, Vol. 10, Núm. 2, pp. 775-788

  2. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  3. Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study)

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 12, pp. 3263-3271

  4. Feasibility of Implementing Long-Acting Injectable Antiretroviral Therapy to Treat HIV: A Survey of Health Providers from the 13 Countries Participating in the ATLAS-2M Trial

    AIDS Research and Human Retroviruses, Vol. 37, Núm. 3, pp. 207-213

  5. Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals

    Liver International, Vol. 41, Núm. 12, pp. 2885-2891

  6. Late HIV diagnosis among immigrants in Spain vs. native-born Spaniards, 2010-15

    European Journal of Public Health, Vol. 31, Núm. 6, pp. 1123-1128